RealWorld Dynamix™: Biologic/Otezla Switching in Psoriasis US 2018 Spotlight II: The Patient Journey
We analyzed the charts of 1,006 US psoriasis patients who were switched from one biologic/small molecule to a different brand in the past three months. Here we highlight one patient record from Spherix’s RealWorld Dynamix: Biologic/Otezla Switching in Psoriasis (US) audit, detailing the patient’s journey from diagnosis to their current switched treatment. In this complimentary infographic, uncover reasons behind why the switch was made, “runner-up” agent had the current treatment not been available, symptoms and quality of life assessment before and after the switch, next likely treatment if the current agent is not successful, and the patient’s mindset throughout the journey
Contact [email protected] for more information about the highlighted report or to see if your company already has acces.
All company, brand or product names and logos in this document are trademarks of their respective holders.